RECRUITING Phase 4 ClinicalTrials.gov

National Liver Cancer Screening Trial

Sponsor: University of Texas Southwestern Medical Center • ClinicalTrials.gov ID: NCT06084234

Registry updated: 2026-09-25

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible patients will be randomized in a 1:1 fashion to Arm A using semi-annual ultrasound and AFP-based screening or Arm B using semi-annual screening using GALAD alone. Randomization will be stratified by sex, enrolling site, Child Pugh class (A vs. B), and HCC etiology (viral vs. non-viral). Patients will be recruited from 15 sites (mix of tertiary care and large community health systems) over a 3-year period, and the primary endpoint of the phase IV trial, reduction in late-stage HCC, will be assessed after 5.5 years.

Interventions

GALAD (Diagnostic test)
GALAD is a 3 biomarker panel incorporating AFP, AFP-L3% and DCP (all FDA approved), with patient age and sex.
Liver Ultrasound with or without AFP (Diagnostic test)
This intervention consists of current standard of care ultrasound based surveillance with or without alpha-fetoprotein measurement.

Eligibility criteria

Inclusion Criteria: Patient must meet all of the following inclusion criteria: 1. Adult patients ages 18-85 with cirrhosis from any etiology or with chronic hepatitis B with a PAGE-B score greater than 9 within 12 months of enrollment 2. Patient is eligible for HCC surveillance according to treating physician or by the site investigator 3. Able to provide informed consent 4. Life expectancy \>6 months (after consent) as determined by the treating provider or site investigator Exclusion Criteria: Patient will be excluded for any of the following exclusion criteria: 1. Child Pugh C cirrhosis 2. History or clinical symptoms of hepatocellular carcinoma or cholangiocarcinoma 3. History of solid nodule on baseline ultrasound (i.e., lesion 1cm or greater) within 9 months prior to consent without subsequent diagnostic CT/MRI demonstrating benign nature) 4. AFP \>20 ng/mL within 6 months prior to consent, in the absence of a contrast-enhanced CT or MRI within 6 months of AFP (before or after) level demonstrating lack of suspicious liver lesions 5. Newly diagnosed LR-3 greater than or equal to 1 cm within 6 months prior to consent 6. History of LR-4, LR-5, or LR-M on multi-phase CT or contrast-enhanced MRI within 6 months prior to consent 7. Presence of another active cancer besides non-melanomatous skin cancer or indolent cancer under active surveillance (e.g., prostate cancer or renal cell carcinoma) within the 2 years prior to consent 8. Patient's provider is planning to use MRI- or CT- based surveillance moving forward 9. History of a transjugular intrahepatic portosystemic shunt (TIPS) 10. History of Fontan associated liver disease or cardiac cirrhosis 11. History of solid organ transplantation 12. Actively listed for liver transplantation 13. Diagnosis of alcohol-associated hepatitis within 3 months prior to consent 14. Documented current or continued signs and symptoms of acute Wilson disease (acute liver failure, acute neurological deficits, hemolysis) 15. In patients with primary sclerosing cholangitis (PSC): Current active cholangitis within 90 days prior to consent 16. Known or documented habitual non-adherence to previous research studies or medical procedures or unwillingness to adhere to protocol (e.g., unwilling to obtain consent or samples) 17. In patients living with HIV: CD4+ T cell count less than 100 cells/mm3 within 60 days prior to consent 18. Known pregnancy at consent 19. Active warfarin use

Conditions

Carcinoma, Hepatocellular Liver Cancer Liver Cirrhosis Hepatitis B

Locations

University of Southern California — Los Angeles, California, United States
Stanford University — Redwood City, California, United States
Kaiser Permanente — Roseville, California, United States
University of California, San Francisco — San Francisco, California, United States
Northwestern University — Chicago, Illinois, United States
Indiana University — Indianapolis, Indiana, United States
Massachusetts General Hospital — Boston, Massachusetts, United States
University of Michigan — Ann Arbor, Michigan, United States
Henry Ford Health System — Detroit, Michigan, United States
Hennepin Healthcare — Minneapolis, Minnesota, United States
University of Minnesota — Minneapolis, Minnesota, United States
The Feinstein Institutes, Northwell Health, Inc. — Manhasset, New York, United States
University of North Carolina — Chapel Hill, North Carolina, United States
Case Western Reserve University — Cleveland, Ohio, United States
The Cleveland Clinic — Cleveland, Ohio, United States
University of Pennsylvania — Philadelphia, Pennsylvania, United States
UT Southwestern Medical Center and Parkland Hospital — Dallas, Texas, United States
Baylor College of Medicine — Houston, Texas, United States
Virginia Commonwealth University — Richmond, Virginia, United States

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment